510(k) device
iPrime Viscodelivery System
Glaukos · Pump, Infusion, Ophthalmic (MRH, Class II) · First FDA decision Jan 6, 2022, newest Jan 6, 2022Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "iPrime Viscodelivery"
MAUDE reports
6
Brand "iPrime Viscodelivery", since 2015
PubMed studies
0
Mentioning "iPrime Viscodelivery"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iPrime Viscodelivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K212797 · Decided Jan 6, 2022 · 126 days after receipt
Device type: Pump, Infusion, Ophthalmic (MRH) · Hospital Medicine & Nursing
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "iPrime Viscodelivery", any status and sponsor, newest update first.
No registered device study names "iPrime Viscodelivery".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iPrime Viscodelivery", and for the whole product code for context.
This brand
6 reports: 2 malfunction, 4 injury, 0 death
Whole product code MRH
140 reports: 44 malfunction, 95 injury, 0 death
Newest reports for this brand
2032546-2024-00026 · Received Mar 12, 2024 · Event dated Feb 22, 2024
Device type: Pump, Infusion, Ophthalmic (MRH)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Eye Injury
- IPRIME VISCODELIVERY SYSTEMMalfunction
2032546-2023-00095 · Received Sep 14, 2023 · Event dated Aug 21, 2023
Device type: Pump, Infusion, Ophthalmic (MRH)
Device problem as coded: Detachment of Device or Device Component
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2032546-2023-00072 · Received Jun 29, 2023 · Event dated Jun 8, 2023
Device type: Pump, Infusion, Ophthalmic (MRH)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Eye Injury
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "iPrime Viscodelivery"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MRH.
- OMNI Surgical SystemSight Sciences, Inc. · 510(k) 2023
- Viscoelastic InjectorSight Sciences, Inc. · 510(k) 2014
- OMNI Ultra Surgical System (1-110)Sight Sciences, Inc. · 510(k) 2026
- VIA360 Surgical SystemNew World Medical, Inc. · 510(k) 2025
- TrabEx ProMicrosurgical Technologies, Inc. · 510(k) 2022
- Streamline Surgical SystemNew World Medical, Inc. · 510(k) 2021
- OMNI PLUS Surgical SystemSight Sciences, Inc. · 510(k) 2020
- VISCO 360 Viscosurgical SystemSight Sciences, Inc. · 510(k) 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.